Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 5 | 2020 | 15 | 1.320 |
Why?
|
| Gynecology | 3 | 2018 | 9 | 0.910 |
Why?
|
| Medical Oncology | 3 | 2018 | 43 | 0.880 |
Why?
|
| Endometrial Neoplasms | 5 | 2022 | 26 | 0.870 |
Why?
|
| Uterine Neoplasms | 2 | 2012 | 17 | 0.720 |
Why?
|
| Ovarian Neoplasms | 5 | 2019 | 78 | 0.710 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 30 | 0.550 |
Why?
|
| Gynecologic Surgical Procedures | 2 | 2016 | 12 | 0.520 |
Why?
|
| Genital Diseases, Female | 1 | 2016 | 5 | 0.520 |
Why?
|
| Registries | 1 | 2018 | 176 | 0.520 |
Why?
|
| Lung Diseases | 1 | 2016 | 43 | 0.500 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 59 | 0.500 |
Why?
|
| Robotic Surgical Procedures | 1 | 2016 | 26 | 0.490 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2016 | 13 | 0.490 |
Why?
|
| Female | 24 | 2022 | 13124 | 0.450 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2022 | 86 | 0.430 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2018 | 33 | 0.430 |
Why?
|
| Uterus | 2 | 2021 | 17 | 0.400 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 98 | 0.380 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2012 | 3 | 0.370 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2012 | 7 | 0.370 |
Why?
|
| Uterine Artery Embolization | 1 | 2011 | 2 | 0.360 |
Why?
|
| Intestinal Fistula | 1 | 2011 | 4 | 0.360 |
Why?
|
| Leiomyoma | 1 | 2011 | 5 | 0.360 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 1 | 0.350 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2011 | 2 | 0.350 |
Why?
|
| Vena Cava Filters | 1 | 2011 | 8 | 0.350 |
Why?
|
| Postoperative Complications | 1 | 2016 | 836 | 0.340 |
Why?
|
| Humans | 24 | 2022 | 23331 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 240 | 0.330 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2010 | 1 | 0.320 |
Why?
|
| DNA Methylation | 1 | 2011 | 128 | 0.320 |
Why?
|
| Middle Aged | 11 | 2019 | 8055 | 0.280 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 311 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 203 | 0.240 |
Why?
|
| Aged | 8 | 2018 | 7552 | 0.210 |
Why?
|
| Adult | 8 | 2018 | 7070 | 0.200 |
Why?
|
| Mutation | 2 | 2022 | 328 | 0.200 |
Why?
|
| Platinum | 1 | 2022 | 4 | 0.190 |
Why?
|
| Paclitaxel | 2 | 2021 | 49 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 3783 | 0.180 |
Why?
|
| Urogenital Abnormalities | 1 | 2021 | 7 | 0.180 |
Why?
|
| Infertility, Female | 1 | 2021 | 21 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2021 | 32 | 0.180 |
Why?
|
| Neoplasms | 1 | 2022 | 221 | 0.160 |
Why?
|
| Folic Acid Deficiency | 1 | 2019 | 6 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 6 | 0.150 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2018 | 2 | 0.150 |
Why?
|
| Hydrazines | 1 | 2018 | 7 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 9 | 0.150 |
Why?
|
| Dextrocardia | 1 | 2018 | 2 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 10 | 0.150 |
Why?
|
| Piperazines | 1 | 2019 | 81 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2016 | 3040 | 0.140 |
Why?
|
| Electrocardiography | 1 | 2018 | 91 | 0.140 |
Why?
|
| Reimbursement Mechanisms | 1 | 2018 | 8 | 0.140 |
Why?
|
| Certification | 1 | 2018 | 24 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 56 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 359 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2021 | 2988 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 198 | 0.130 |
Why?
|
| Hysterectomy | 2 | 2021 | 25 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1038 | 0.130 |
Why?
|
| Genetic Testing | 2 | 2016 | 45 | 0.130 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 28 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2018 | 127 | 0.130 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.130 |
Why?
|
| DNA Mismatch Repair | 2 | 2016 | 10 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 246 | 0.120 |
Why?
|
| Illinois | 1 | 2016 | 221 | 0.120 |
Why?
|
| Survival Rate | 2 | 2021 | 323 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 100 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 164 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2016 | 183 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2013 | 200 | 0.110 |
Why?
|
| Incidence | 1 | 2016 | 636 | 0.110 |
Why?
|
| Cervix Mucus | 1 | 2013 | 4 | 0.100 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2013 | 3 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2013 | 50 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2013 | 25 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2013 | 125 | 0.100 |
Why?
|
| United States | 1 | 2018 | 1829 | 0.090 |
Why?
|
| Pedigree | 1 | 2012 | 52 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2022 | 338 | 0.090 |
Why?
|
| Bevacizumab | 2 | 2022 | 22 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2011 | 12 | 0.090 |
Why?
|
| Sirolimus | 2 | 2022 | 20 | 0.090 |
Why?
|
| Vagina | 1 | 2011 | 31 | 0.090 |
Why?
|
| Intestine, Small | 1 | 2011 | 31 | 0.090 |
Why?
|
| Azacitidine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Risk Factors | 1 | 2016 | 1998 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 86 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 132 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 116 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 113 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 82 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 246 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 62 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1441 | 0.080 |
Why?
|
| Morbidity | 1 | 2010 | 51 | 0.080 |
Why?
|
| Patient Care | 1 | 2010 | 29 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2020 | 66 | 0.080 |
Why?
|
| Tomography, X-Ray | 1 | 2009 | 2 | 0.080 |
Why?
|
| Prognosis | 1 | 2012 | 740 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 73 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2010 | 565 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2012 | 1523 | 0.070 |
Why?
|
| Quality of Life | 2 | 2020 | 560 | 0.060 |
Why?
|
| Young Adult | 1 | 2011 | 1674 | 0.060 |
Why?
|
| Vulvar Diseases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Granuloma | 1 | 2005 | 13 | 0.060 |
Why?
|
| Medical Futility | 1 | 2022 | 5 | 0.050 |
Why?
|
| Strategic Planning | 1 | 2021 | 7 | 0.050 |
Why?
|
| Epothilones | 1 | 2021 | 2 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 24 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 20 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2021 | 19 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2021 | 16 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 251 | 0.040 |
Why?
|
| Folic Acid | 1 | 2019 | 21 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 26 | 0.040 |
Why?
|
| Heart | 1 | 2018 | 59 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2016 | 51 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 6 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 8 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 4 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 8 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 10 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 47 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 73 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 68 | 0.030 |
Why?
|
| Male | 1 | 2011 | 12629 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 230 | 0.030 |
Why?
|
| Metaplasia | 1 | 2013 | 7 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 53 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 257 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 262 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 380 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 442 | 0.020 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Colposcopy | 1 | 2011 | 3 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2011 | 12 | 0.020 |
Why?
|
| Dyspareunia | 1 | 2005 | 6 | 0.010 |
Why?
|
| Analgesics | 1 | 2005 | 78 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 272 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 389 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2005 | 418 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 258 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2005 | 293 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 1429 | 0.010 |
Why?
|